Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig
The aim of our study was to evaluate the effects of thromboxane A2 (TXA2) agonist, U-46619, on systemic circulatory parameters in the pigs before and after administration of a novel TXA2 receptor antagonist and synthase inhibitor (BM-573). Twelve anesthetized pigs were randomly assigned in two groups: in Ago group (n=6), the animals received six consecutive injections of U-46619 at 30 min interval, while in Anta group (n=6) they received an increasing dosage regimen of BM-573 10 min before each U-46619 injection. The effects of each dose of BM-573 on ex vivo platelet aggregation induced by arachidonic acid, collagen or ADP were also evaluated. Vascular properties such as characteristic impedance, peripheral resistance, compliance, arterial elastance were estimated using a windkessel model. Intravenous injections of 0.500 mg/ml of BM-573 and higher doses resulted in a complete inhibition of platelet aggregation induced by arachidonic acid. In the same conditions, BM-573 completely blocked the increase of arterial elastance, and stabilized both mean aortic blood pressure and mean systemic blood flow. In conclusion, BM-573 could therefore be a promising therapeutic approach in pathophysiological states where TXA2 plays a main role in the increase of vascular resistance like in pathologies such as systemic hypertension.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2005 |
|---|---|
| Erschienen: |
2005 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Prostaglandins & other lipid mediators - 78(2005), 1-4 vom: 22. Dez., Seite 82-95 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tchana-Sato, Vincent [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 17.04.2006 Date Revised 20.11.2014 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM159083575 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM159083575 | ||
| 003 | DE-627 | ||
| 005 | 20231223083433.0 | ||
| 007 | tu | ||
| 008 | 231223s2005 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0530.xml |
| 035 | |a (DE-627)NLM159083575 | ||
| 035 | |a (NLM)16303607 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tchana-Sato, Vincent |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig |
| 264 | 1 | |c 2005 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2006 | ||
| 500 | |a Date Revised 20.11.2014 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The aim of our study was to evaluate the effects of thromboxane A2 (TXA2) agonist, U-46619, on systemic circulatory parameters in the pigs before and after administration of a novel TXA2 receptor antagonist and synthase inhibitor (BM-573). Twelve anesthetized pigs were randomly assigned in two groups: in Ago group (n=6), the animals received six consecutive injections of U-46619 at 30 min interval, while in Anta group (n=6) they received an increasing dosage regimen of BM-573 10 min before each U-46619 injection. The effects of each dose of BM-573 on ex vivo platelet aggregation induced by arachidonic acid, collagen or ADP were also evaluated. Vascular properties such as characteristic impedance, peripheral resistance, compliance, arterial elastance were estimated using a windkessel model. Intravenous injections of 0.500 mg/ml of BM-573 and higher doses resulted in a complete inhibition of platelet aggregation induced by arachidonic acid. In the same conditions, BM-573 completely blocked the increase of arterial elastance, and stabilized both mean aortic blood pressure and mean systemic blood flow. In conclusion, BM-573 could therefore be a promising therapeutic approach in pathophysiological states where TXA2 plays a main role in the increase of vascular resistance like in pathologies such as systemic hypertension | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a N-terbutyl-N'-(2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl)urea |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Sulfonylurea Compounds |2 NLM | |
| 650 | 7 | |a Thromboxane A2 |2 NLM | |
| 650 | 7 | |a 57576-52-0 |2 NLM | |
| 650 | 7 | |a 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid |2 NLM | |
| 650 | 7 | |a 76898-47-0 |2 NLM | |
| 700 | 1 | |a Dogné, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Lambermont, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Ghuysen, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Magis, David |e verfasserin |4 aut | |
| 700 | 1 | |a Morimont, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Hanson, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a D'Orio, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Limet, Raymond |e verfasserin |4 aut | |
| 700 | 1 | |a Kolh, Philippe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Prostaglandins & other lipid mediators |d 1998 |g 78(2005), 1-4 vom: 22. Dez., Seite 82-95 |w (DE-627)NLM095840443 |x 1098-8823 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2005 |g number:1-4 |g day:22 |g month:12 |g pages:82-95 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2005 |e 1-4 |b 22 |c 12 |h 82-95 | ||